- Home
- ROOT vs GYRE Comparison
ROOT vs GYRE Comparison
Compare ROOT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- GYRE
- Stock Information
- Founded
- ROOT 2015
- GYRE 2002
- Country
- ROOT United States
- GYRE United States
- Employees
- ROOT N/A
- GYRE N/A
- Industry
- ROOT Property-Casualty Insurers
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- GYRE Health Care
- Exchange
- ROOT Nasdaq
- GYRE Nasdaq
- Market Cap
- ROOT 1.3B
- GYRE 1.1B
- IPO Year
- ROOT 2020
- GYRE N/A
- Fundamental
- Price
- ROOT $83.32
- GYRE $11.19
- Analyst Decision
- ROOT Buy
- GYRE
- Analyst Count
- ROOT 9
- GYRE 0
- Target Price
- ROOT $58.38
- GYRE N/A
- AVG Volume (30 Days)
- ROOT 306.2K
- GYRE 110.3K
- Earning Date
- ROOT 02-19-2025
- GYRE 11-13-2024
- Dividend Yield
- ROOT N/A
- GYRE N/A
- EPS Growth
- ROOT N/A
- GYRE N/A
- EPS
- ROOT N/A
- GYRE N/A
- Revenue
- ROOT $1,044,599,999.00
- GYRE $105,033,000.00
- Revenue This Year
- ROOT N/A
- GYRE $25.32
- Revenue Next Year
- ROOT $8.20
- GYRE $12.95
- P/E Ratio
- ROOT N/A
- GYRE N/A
- Revenue Growth
- ROOT 215.11
- GYRE N/A
- 52 Week Low
- ROOT $7.22
- GYRE $8.26
- 52 Week High
- ROOT $118.15
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- ROOT 54.00
- GYRE 51.52
- Support Level
- ROOT $77.57
- GYRE $10.41
- Resistance Level
- ROOT $89.92
- GYRE $11.36
- Average True Range (ATR)
- ROOT 5.65
- GYRE 0.69
- MACD
- ROOT 0.66
- GYRE 0.09
- Stochastic Oscillator
- ROOT 63.67
- GYRE 60.22
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.